Loading…
Loading…
HTSUF (Hisamitsu Pharmaceutical Co., Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HTSUF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HTSUF and 80,000+ other tickers.
See exactly how HTSUF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HTSUF and 80,000+ other tickers.
Hisamitsu Pharmaceutical Co., Inc. is a Japanese enterprise that develops and markets a range of pharmaceuticals, quasi-drugs, and medical devices. Its extensive product catalog includes popular external pain relief solutions such as SALONPAS, NOBINOBI, SALONSIP, AIR, and FEITAS. The company also provides targeted treatments like BUTENALOCK for athlete's foot and ALLEGRA FX, a medication addressing sinus and allergy symptoms. Furthermore, Hisamitsu produces various quasi-pharmaceuticals and cosmetic items. A core specialization lies in transdermal patch technology, offering analgesic…
Hisamitsu Pharmaceutical Co. (HTSUF) said it will pursue a management buyout that could take the Japanese pain-relief patch maker private, a move that sent its
Japan's Hisamitsu Pharmaceutical is planning to take the company private in a management buyout for nearly 400 billion yen ($2.55 billion), it said in a filing late on Tuesday.